Clinical Trial Update: Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating HZT-501 to reduce the risk of ibuprofen-associated peptic ulcers has completed with posted efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peptic Ulcer Disease

Drugs mentioned

• HZT-501

Snippet

Sponsor: Amgen | Conditions: Peptic Ulcer | Phase 3 | Status: COMPLETED | Results posted: 2011-06-21